Dusseldorf - Delayed Quote EUR

Maat Pharma SA (4RD.DU)

Compare
7.88
-0.10
(-1.25%)
At close: January 24 at 8:11:48 AM GMT+1
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for 4RD.DU

Recent News: 4RD.DU

View More
MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT
Business Wire 3 days ago
Maat Pharma Phase III microbiome trial hits endpoints as stock soars

Maat Pharma Phase III microbiome trial hits endpoints as stock soars
Clinical Trials Arena 16 days ago
MaaT Pharma Announces Positive Topline Results from the Pivotal Phase 3 ARES Study Evaluating MaaT013 in acute Graft-versus-Host Disease

MaaT Pharma Announces Positive Topline Results from the Pivotal Phase 3 ARES Study Evaluating MaaT013 in acute Graft-versus-Host Disease
Business Wire 16 days ago
MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
Business Wire 17 days ago
CORRECTING and REPLACING: MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting

CORRECTING and REPLACING: MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting
Business Wire last month
MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting

MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting
Business Wire last month
MaaT Pharma Announces First U.S. Patient Treated at City of Hope Under Single Patient Expanded Access for MaaT013 in Acute Graft-versus-Host Disease

MaaT Pharma Announces First U.S. Patient Treated at City of Hope Under Single Patient Expanded Access for MaaT013 in Acute Graft-versus-Host Disease
Business Wire last month
MaaT Pharma eyes Phase II after early success in ALS microbiome trial

MaaT Pharma eyes Phase II after early success in ALS microbiome trial
Clinical Trials Arena last month
MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS)

MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS)
Business Wire last month
MaaT Pharma to Present Updates from Early Access Program at the 2024 ASH Annual Meeting Demonstrating Prolonged Long-Term Survival in Patients Receiving MaaT013 in aGvHD

MaaT Pharma to Present Updates from Early Access Program at the 2024 ASH Annual Meeting Demonstrating Prolonged Long-Term Survival in Patients Receiving MaaT013 in aGvHD
Business Wire 2 months ago
MaaT Pharma Provides Third Quarter 2024 Business and Financial Results and Announces Management Changes

MaaT Pharma Provides Third Quarter 2024 Business and Financial Results and Announces Management Changes
Business Wire 2 months ago
View More